Project 2: Abscisic Acid Regulates Dormancy of Disseminated Tumor Cells in Bone Marrow

项目2:脱落酸调节骨髓中播散性肿瘤细胞的休眠

基本信息

  • 批准号:
    10208784
  • 负责人:
  • 金额:
    $ 15.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-06-05 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

Abstract: Abscisic Acid Regulates Dormancy of Disseminated Tumor Cells in Bone Marrow Prostate cancer (PCa) preferentially metastasizes to the bone marrow. Paget's “seed and soil hypothesis” in 1889 has been used to describe tumor cells (i.e. seed) metastasize to bone marrow (i.e. soil), which have specific factors conducive to metastatic growth. Recently, abscisic acid (ABA), a phytohormone, regulates the dormancy of plant seeds and other stress responses was demonstrated to be expressed in mammals where it inhibits proliferation of many cell types. Our data shows that ABA induces PCa cell cycle arrest in G0, regulates PCa survival in response to chemotherapy, and ABA receptors (LANCL2, PPAR) are expressed by DTCs recovered from human marrow. Further ABA expression may represent a common pathway for dormancy mediators (e.g. TGFß, GAS6, BMP4). The central hypothesis is: Abscisic acid induces dormancy of metastatic DTCs in the bone marrow. Aim 1: Determine the extent to which ABA induces PCa dormancy in bone marrow. Subhypothesis: ABA is critical for establishing DTC dormancy. Approach: Coculture studies and in vivo metastasis model s will explore the role of ABA in establishing DTC dormancy and how regulates cancer stem cell (CSC)-like activities. In vivo studies will be examine the role that niche-produced ABA plays in the maintenance of DTC dormancy. We will validate these observations with DTCs isolated from marrow of PCa patients. Aim 2: Determine the extent to which ABA signaling through LANCL2 or PPAR receptors induces dormancy of PCa cells in the marrow. Subhypothesis: The binding of ABA to its receptors are critical for DTCs to become dormant. Approach: In Aim 2A: we will defined the role that each ABA receptor plays in regulating dormancy and what are the downstream signals, and in Aim 2B, we will determine what transcription pathways are activated by ABA to induce DTC Aim 3: Define the role of ABA signaling in resistance of PCa to chemotherapy in bone marrow. Subhypothesis: Dormant PCa cells are resistant to chemotherapy. Approach: We will to evaluate whether the disruption of DTC dormancy by ABA or ABA signaling will improve treatment outcomes by sensitizing dormant PCa cells to current chemotherapies.
摘要:脱落酸调节骨髓中播散性肿瘤细胞的休眠 前列腺癌(PCa)优先转移到骨髓。佩吉特的“种子和土壤假说”, 1889已经被用于描述肿瘤细胞(即种子)转移到骨髓(即土壤),其具有 有助于转移性生长的特定因素。最近,脱落酸(阿坝),一种植物激素,调节 植物种子休眠和其他应激反应被证明在哺乳动物中表达, 抑制多种细胞类型的增殖。我们的数据表明,阿坝诱导PCa细胞周期阻滞在G0期,调节 PCa对化疗的存活率,以及DTC表达阿坝受体(LANCL 2,PPAR γ) 从人类骨髓中提取的阿坝的进一步表达可能代表了休眠的共同途径 介质(例如TGF β、GAS 6、BMP 4)。核心假设是: 脱落酸诱导骨髓中转移性DTC休眠。 目的1:确定阿坝诱导骨髓中PCa休眠的程度。次假设: 阿坝是建立DTC休眠的关键。方法:共培养研究和体内转移模型 将探讨阿坝在建立DTC休眠中的作用以及如何调节癌症干细胞(CSC)样 活动在体内研究中,将检查小生境产生的阿坝在DTC维持中的作用 休眠我们将用从PCa患者骨髓中分离的DTC验证这些观察结果。 目的2:确定阿坝信号通过LANCL 2或PPAR γ受体诱导的程度。 骨髓中PCa细胞的休眠。亚假设:阿坝与其受体的结合对于 DTC将休眠。方法:在目标2A中:我们将定义每个阿坝受体在 调节休眠和下游信号是什么,在目标2B中,我们将确定什么转录 阿坝可激活这些通路,诱导DTC 目的3:明确骨髓中阿坝信号在前列腺癌化疗耐药中的作用。 亚假设:Doradian PCa细胞对化疗耐药。方法:我们将评估 通过阿坝或阿坝信号传导破坏DTC休眠将通过敏化 休眠的前列腺癌细胞对目前的化疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RUSSELL S TAICHMAN其他文献

RUSSELL S TAICHMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RUSSELL S TAICHMAN', 18)}}的其他基金

Mechanisms That Regulate Dormancy of Disseminated Tumor Cells in the Bone Marrow
调节骨髓中播散性肿瘤细胞休眠的机制
  • 批准号:
    8555281
  • 财政年份:
    2011
  • 资助金额:
    $ 15.97万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8555283
  • 财政年份:
    2011
  • 资助金额:
    $ 15.97万
  • 项目类别:
Regulation of the PCa Metastatic Phenotype by the HSC Niche
HSC 生态位对 PCa 转移表型的调节
  • 批准号:
    8854468
  • 财政年份:
    2004
  • 资助金额:
    $ 15.97万
  • 项目类别:
Prostate Cancer Parasitism of the HSC "niche" as a Molecular Mechanism for Ost
前列腺癌 HSC“生态位”的寄生作为 Ost 的分子机制
  • 批准号:
    8066734
  • 财政年份:
    2004
  • 资助金额:
    $ 15.97万
  • 项目类别:
Project 2: Abscisic Acid Regulates Dormancy of Disseminated Tumor Cells in Bone Marrow
项目2:脱落酸调节骨髓中播散性肿瘤细胞的休眠
  • 批准号:
    10629254
  • 财政年份:
    2004
  • 资助金额:
    $ 15.97万
  • 项目类别:
Prostate Cancer Parasitism of the HSC "niche" as a Molecular Mechanism for Ost
前列腺癌 HSC“生态位”的寄生作为 Ost 的分子机制
  • 批准号:
    7659013
  • 财政年份:
    2004
  • 资助金额:
    $ 15.97万
  • 项目类别:
Project 2: Abscisic Acid Regulates Dormancy of Disseminated Tumor Cells in Bone Marrow
项目2:脱落酸调节骨髓中播散性肿瘤细胞的休眠
  • 批准号:
    10427245
  • 财政年份:
    2004
  • 资助金额:
    $ 15.97万
  • 项目类别:
Role of SDF-1/CSCR4 in bone metastasis
SDF-1/CSCR4在骨转移中的作用
  • 批准号:
    6990045
  • 财政年份:
    2004
  • 资助金额:
    $ 15.97万
  • 项目类别:
Prostate Cancer Parasitism of the HSC "niche" as a Molecular Mechanism for Ost
前列腺癌 HSC“生态位”的寄生作为 Ost 的分子机制
  • 批准号:
    8377419
  • 财政年份:
    2004
  • 资助金额:
    $ 15.97万
  • 项目类别:
Prostate Cancer Parasitism of the HSC "niche" as a Molecular Mechanism for Ost
前列腺癌 HSC“生态位”的寄生作为 Ost 的分子机制
  • 批准号:
    8284222
  • 财政年份:
    2004
  • 资助金额:
    $ 15.97万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 15.97万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 15.97万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 15.97万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 15.97万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 15.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 15.97万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 15.97万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 15.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 15.97万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 15.97万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了